Research ArticleDrug Discovery and Translational Medicine
Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APCmin/+ Mouse Intestinal Tumorigenesis
Durgadevi Ravillah, Altaf Mohammed, Li Qian, Misty Brewer, Yuting Zhang, Laura Biddick, Vernon E. Steele and Chinthalapally V. Rao
Journal of Pharmacology and Experimental Therapeutics January 2014, 348 (1) 59-68; DOI: https://doi.org/10.1124/jpet.113.208645
Durgadevi Ravillah
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Altaf Mohammed
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Li Qian
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Misty Brewer
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Yuting Zhang
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Laura Biddick
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Vernon E. Steele
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Chinthalapally V. Rao
Hematology-Oncology Section, Department of Medicine, Center for Cancer Prevention and Drug Development, PCS Oklahoma Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (D.R., A.M., L.Q., M.B., Y.Z., L.B., C.V.R.); and Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Institutes of Health National Cancer Institute, Bethesda, Maryland (V.E.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Chemoprevention of Colon Carcinogenesis by an HDAC2-Selective Inhibitor
Durgadevi Ravillah, Altaf Mohammed, Li Qian, Misty Brewer, Yuting Zhang, Laura Biddick, Vernon E. Steele and Chinthalapally V. Rao
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 59-68; DOI: https://doi.org/10.1124/jpet.113.208645
Research ArticleDrug Discovery and Translational Medicine
Chemoprevention of Colon Carcinogenesis by an HDAC2-Selective Inhibitor
Durgadevi Ravillah, Altaf Mohammed, Li Qian, Misty Brewer, Yuting Zhang, Laura Biddick, Vernon E. Steele and Chinthalapally V. Rao
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 59-68; DOI: https://doi.org/10.1124/jpet.113.208645
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement